This content is only available within our institutional offering.
06 Nov 2018
LIBERUM: Something worth saying in pharma - Cancer gold-rush adds pressure for pharma to diversify
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
LIBERUM: Something worth saying in pharma - Cancer gold-rush adds pressure for pharma to diversify
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
06 Nov 2018 -
Author:
Graham Doyle -
Pages:
4